NYSEAMERICAN:HEB - Hemispherx BioPharma Stock Price, Forecast & News

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

Hemispherx BioPharma's stock reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter. View Hemispherx BioPharma's Earnings History.

2 brokers have issued 12-month price targets for Hemispherx BioPharma's stock. Their forecasts range from $6.00 to $8.00. On average, they expect Hemispherx BioPharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 872.2% from the stock's current price. View Analyst Price Targets for Hemispherx BioPharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hemispherx BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hemispherx BioPharma.

Media coverage about HEB stock has trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hemispherx BioPharma earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Hemispherx BioPharma.

Some companies that are related to Hemispherx BioPharma include Nanollose (NC6), Biopharmx (BPMX), Nuvo Pharmaceuticals (NRI), Innovotech (IOT), Fiji Kava (FIJ), Netscientific (NSCI), Hemostemix (HEM), Amplia Therapeutics (ATX), Factor Therapeutics (FTT), Pascal Biosciences (PAS), CAN-FITE BIOPHA/S (CANF), Revive Therapeutics (RVV), Can-Fite Biopharma (CANF), IBEX Technologies (IBT) and BPH Energy (BPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Cytori Therapeutics (CYTX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Biopharmx (BPMX), NovaBay Pharmaceuticals (NBY) and Palatin Technologies (PTN).

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HEB stock can currently be purchased for approximately $0.72.

Hemispherx BioPharma has a market capitalization of $1.76 million. Hemispherx BioPharma employs 31 workers across the globe.View Additional Information About Hemispherx BioPharma.

The official website for Hemispherx BioPharma is http://www.hemispherx.net/.

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.